Increasing Prevalence of Chronic Diseases and Trauma Conditions Likely to Boost the Oxycodone Market Growth
A rise in the number of patients suffering from terminally-ill diseases, such as cancer and HIV, and a high surge in post-operative pain medication prescription is expected to boost the consumption of oxycodone as a analgesics.
According to the Center for Disease Control and Prevention, in 2013, there were 239 million surgeries conducted across the globe, out of which 69 million were conducted in the U.S. Out of all these 239 million surgeries, around 65% of the patients experienced moderate to severe post-operative pain. This factor fuels the adoption of opioid pain management drugs and indirectly expands the growth of the oxycodone market.
Abusive Consumption of Opioids Drugs a Cause of Concern for the Oxycodone Market Growth
Concerns over opioid abuse and associated mortality are the primary constraints for the growth of the oxycodone market. Opioid abuse resulted in approximately 49,000 of the 72,000 drug overdose deaths in the U.S. in 2017. Almost 66% of the drug overdose deaths in 2017 involved an opioid. On an average, 115 Americans die per day from opioid abuse.
New Drug Development and Government Support Drives the Oxycodone Market
New drug development is a large market opportunity for the oxycodone market. New products with innovations in formulations and drug designing such as, abuse–deterrent formulations done in Oxycontin and Opana, fuel the branded opiate market. Moreover, the U.S. Food and Drug Administration is also encouraging drug makers to come up with a new generation drug that is less addictive.
An increase in new drug applications by pharmaceutical companies and the number of products in the pipeline drives the oxycodone market. Other formulations such as control release of drugs for improved pain management are coming up in the market. Advanced drug formulations such as extended-release medications for pain control are examples of improved formulation driving the market.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
Strong Penetration of Pain Management Drugs Coupled with Attractive Reimbursements
In the North American oxycodone market, the U.S. is the dominant market due to its large economy and purchasing power. The excellent reimbursement and growing incidence of oxycodone are also expected to support the growth of the oxycodone market. The presence of large players such as Purdue Pharma, Pfizer Inc., Janssen Pharmaceuticals Inc., Endo Pharmaceuticals, and others is also expected to drive the growth of the oxycodone market in the U.S. The healthcare expenditure in the U.S. was almost 16 % of its GDP in 2017, which amply reflects better pricing and market attractiveness for the oxycodone market.
The growing healthcare infrastructure as well as healthcare expenditure of Europe, which accounts to an average 10% of its GDP, is driving the growth of the European oxycodone market. Other European nations with a sizeable oxycodone market are France, the U.K., Italy, and Spain.
The Asia Pacific Oxycodone market is dominated by Japan, India, Australia, and New Zealand. The Middle East and Africa oxycodone market is dominated by the Gulf countries owing to their high wealth and large public healthcare expenditure, which is approximately 75% of the GDP. The development of large specialty hospitals with greater purchasing power is driving the faster adoption of oxycodone products. The consolidation of large healthcare providers coupled with greater healthcare insurance penetration is another driver for the oxycodone market.
Poor Efficacy and Efficiency of Treatment is the Biggest Barrier to Achieve Full Oxycodone Market Potential
Oxycodone adoption is limited due to its poor efficacy, abuse potential and side effects such as opioids induced constipation, nausea, itching, and sweating. However, an increase in non-medical prescription opioid use is driving the larger market growth.
In 2014, a total of 10.3 million persons reported using prescription opioids non medically as per the National Institute of Drug Abuse. Non-medical use of prescription opioids more than doubled among adults in the United States from 2001-2002 to 2012-2013. This has directly shown an increase in net sales
The competition section of the oxycodone market features profiles of key players operating in the industry based on their market shares, differential strategies, product offerings, marketing approach, and company dashboard. Some of the key players operating in the oxycodone market include Pfizer Inc., Teva Pharmaceutical Industries Ltd., Purdue Pharma L.P, Daiichi Sankyo, Acorda Therapeutics, Teikoku Pharma USA, Inc., Mylan N.V., Endo Pharmaceuticals Inc., and Janssen Pharmaceuticals, Inc.
Oxycodone is an opioid available in oral liquid formulations or as oral solid dosage forms and is used to offer enhanced pain management. The major types of oxycodone based on their mechanism of action are long-acting oxycodone and short-acting oxycodone. These have evolved back in 1990, but they became significant and the market for oxycodone boomed over past ten years. Effective sales of oxycodone for major applications such as pain management and de-addiction began in 2000. Thus, in our scope of study we have looked into the historical market value from year 2013 and forecasted the market till 2028 based on certain forecast factors mentioned further in the report.
About the Report
FMI conducted a research study on the oxycodone market for the forecast period 2018 to 2022. The oxycodone market report offers a comprehensive evaluation of the business opportunities prevailing in the oxycodone market along with insights on the oxycodone consumption trend, disease incidences, and awareness level for Oxycodone market competition. The report elaborates on the macroeconomic factors influencing the dynamics of oxycodone market and its futuristic potential.
Additional Questions Answered
Some of the additional questions addressed in this report on oxycodone market-
- What is the revenue potential of point-of-care oxycodone across regions of North America and Europe?
- Who are the key competitors and what are their portfolios in oxycodone market?
- What are major challenges influencing the growth of oxycodone market?
- How intervention from regulatory authority is shaping the oxycodone market growth?
The oxycodone market has been estimated based on the supply-demand approach. The market was first calculated based on incidence and diagnosis rate, conducted in different region/countries. Other qualitative factors analyzed during the estimation include treatment rates for oxycodone, recurrence rate and others.
This information is further validated with rigorous primary research (including interviews, surveys, in-person interactions, and viewpoints of seasoned analysts) and secondary research (including verified paid sources, authentic trade journals, and resourceful databases).
The research study on the oxycodone market also includes top trends and macro as well as micro economic factors shaping the oxycodone market. With this approach, the report on the oxycodone market anticipates the industry attractiveness of every major segment in oxycodone over the forecast period.
The report offers a comprehensive taxonomy of the oxycodone market based on product type, applications, distribution channels, and region. The product type segment of the oxycodone market includes long-acting oxycodone, and short-acting oxycodone. The applications segment of the oxycodone market is segmented by pain management and de-addiction. The distribution channel segment of the oxycodone market includes hospitals pharmacies and retail pharmacies.
The oxycodone market has been analyzed across regions of North America, Latin America, Europe, Asia Pacific, and MEA.